The company said it believes three doses “may provide a higher level of protection in this age group.”
![Kids drawings hang on a wall as a boy is vaccinated, in a vaccination center, in Nantes, western France, Thursday, Dec. 30, 2021. France has vaccinated 77% of its population and is rushing out booster shots. But more than 4 million adults remain unvaccinated. (AP Photo/Jeremias Gonzales)](https://res.cloudinary.com/graham-media-group/image/upload/f_auto/q_auto/c_scale,w_792/v1/media/gmg/FMQL77HEIJADZM3XNDXXWAHQCQ.jpg?_a=ATABlAA0)
The move means that vaccines for this age group will not be available in the coming weeks, a setback for parents eager to vaccinate their young children.
Pfizer said on Friday that it will wait for its data on a three-dose series of the vaccine, because it believes three doses “may provide a higher level of protection in this age group.” Data on the third dose is expected in early April, the company said.